Regulatory Sensitivity Matrix
Sorted by sensitivity descending. High-sensitivity entries include POM-adjacent compounds (GLP-1 agonists, PT-141) and combinations using them.
Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.
Regulatory sensitivity flags compounds and stacks that attract — or are likely to attract — MHRA scrutiny under the medicinal-product definition or POM advertising rules. High sensitivity means a UK or US/EU prescription-only medicine is in the combination, active enforcement against public-facing UK marketing exists, or both.Moderate means an unapproved compound with credible medicinal claims; low means a compound with limited regulatory exposure as currently positioned. This is not a legal opinion. See UK regulation hub, POM advertising rules, borderline products.
| Compound / stack | Approval | Sensitivity | Note | |
|---|---|---|---|---|
| Peptide | Cerebrolysin — Porcine-Brain Neuropeptide Preparation | not-approved | high | Approved as a medicinal product in 40+ jurisdictions including Austria, Russia, China, Czech Republic, Mexico (post-stroke + cognitive indications). NOT licensed in UK or US — MHRA Special Authorisation required for UK import. Laboratory research use only outside approved territories. |
| Peptide | Melanotan II — Broad-Spectrum α-MSH Analogue | not-approved | high | Unapproved globally. MHRA enforcement priority for sales presented as a tanning agent for human use. Research and laboratory use only — never sell as cosmetic, supplement, or for human administration. |
| Peptide | PT-141 (Bremelanotide) — MC4R-Selective Melanocortin Agonist | unclear | high | FDA-approved as Vyleesi (2019) for premenopausal HSDD. Not licensed in UK by MHRA — research use only outside US. |
| Peptide | Retatrutide — Triple GIP/GLP-1/Glucagon Receptor Agonist | unclear | high | Phase III ongoing (2026). Unapproved globally as of May 2026. Research-grade material is unapproved for human medicinal use. |
| Peptide | Tesamorelin — Stabilised GHRH Analogue (EGRIFTA) | unclear | high | FDA-approved (EGRIFTA, 2010) for HIV-associated lipodystrophy. EU/UK availability limited. Outside this indication, research use only. |
| Peptide | Thymosin α-1 — Thymic Immunomodulatory Peptide (Zadaxin / Thymalfasin) | not-approved | high | Approved as a medicinal product in 30+ countries (Zadaxin/Thymalfasin) for hepatitis B and C, primarily Italy, China, Mexico, Argentina. NOT approved in UK or US — research use only. |
| Peptide | Tirzepatide — Dual GIP/GLP-1 Receptor Agonist (Mounjaro / Zepbound) | approved | high | UK MHRA licensed (Mounjaro) for type 2 diabetes and obesity. FDA-approved as Mounjaro (T2DM) and Zepbound (chronic weight management). Research-grade material falls outside the licensed product authorisation. |
| Stack | BPC-157 + KPV + Thymosin α-1 — Research Evidence Review: Immune & Mucosal Mechanisms | not-approved | high | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | CJC-1295 + Ipamorelin + Tesamorelin — Research Evidence Review: GH Axis Mechanisms & Study Limitations | not-approved | high | Direct combination evidence is limited (mostly preclinical / small-trial). |
| Stack | Cerebrolysin + Semax — Research Evidence Review: Neuropeptide & BDNF-Axis Mechanisms | not-approved | high | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | Melanotan II + Bremelanotide — Research Evidence Review: Melanocortin Mechanisms & Safety Signals | not-approved | high | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | PT-141 + Kisspeptin-10 — Research Evidence Review: Melanocortin & Reproductive-Axis Mechanisms | not-approved | high | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | Tesamorelin + AOD-9604 — Research Evidence Review: Visceral Adipose Research Context | not-approved | high | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | Tirzepatide + Retatrutide + AOD-9604 — Research Evidence Review: Incretin & Lipolytic Mechanisms (UK POM sensitivity) | unclear | high | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Peptide | AOD-9604 — Growth Hormone C-terminal Lipolytic Fragment | not-approved | moderate | Granted GRAS status in the US (food/cosmetic), not approved as a medicinal product. Unapproved in UK/EU for therapeutic use. Research use only. |
| Peptide | BPC-157 — Body Protection Compound 157 | not-approved | moderate | Unapproved research compound in UK (MHRA), US (FDA) and EU (EMA). For in vitro laboratory research only. |
| Peptide | CJC-1295 — GHRH(1-29) Analogue (no DAC / DAC variants) | not-approved | moderate | Unapproved research compound in UK, US, EU. Laboratory research use only. Distinct from medicinally-approved Tesamorelin. |
| Peptide | DSIP — Delta Sleep-Inducing Peptide | not-approved | moderate | Unapproved research compound in UK, US, EU. Laboratory research use only. |
| Peptide | Epitalon — Pineal Tetrapeptide Bioregulator | not-approved | moderate | Khavinson group has medicinal-product approval for related bioregulators in the Russian Federation. Epitalon itself remains an unapproved research compound in UK, US, EU. |
| Peptide | GHK-Cu — Copper Tripeptide-1 | not-approved | moderate | Topical cosmetic use legal in UK / EU / US (multiple commercial dermal products). Injectable research-grade peptide remains unapproved for human medicinal use. |
| Peptide | Humanin — Mitochondrial-Derived 24-Amino-Acid Peptide | not-approved | moderate | Unapproved research compound globally. Laboratory and in vitro use only. |
| Peptide | Ipamorelin — Selective Growth Hormone Secretagogue | not-approved | moderate | Unapproved research compound globally. For in vitro and laboratory research only. |
| Peptide | Kisspeptin-10 — GnRH-Axis Hypothalamic Decapeptide | not-approved | moderate | Unapproved research compound in UK, US, EU — extensive clinical research (Dhillo, Imperial College) but no marketing authorisation. Laboratory research use only. |
| Peptide | KPV — α-MSH(11-13) C-Terminal Anti-Inflammatory Tripeptide | not-approved | moderate | Unapproved research compound in UK, US, EU. Laboratory and in vitro research use only. |
| Peptide | LL-37 — Human Cathelicidin Antimicrobial Peptide | not-approved | moderate | Unapproved research compound in UK, US, EU. Laboratory and in vitro research use only. |
| Peptide | MOTS-c — Mitochondrial Open Reading Frame 12S rRNA-c | not-approved | moderate | Unapproved research compound globally. Laboratory research use only. |
| Peptide | Pinealon — Pineal Tripeptide Bioregulator | not-approved | moderate | Khavinson group has medicinal-product approval for related bioregulators in the Russian Federation. Pinealon itself remains an unapproved research compound in UK, US, EU. |
| Peptide | Selank — Tuftsin-Derivative Anxiolytic Heptapeptide | not-approved | moderate | Approved in Russian Federation as a medicinal product (anxiolytic indication). Unapproved in UK, US, EU — laboratory research use only. |
| Peptide | Semax — ACTH(4-10) Heptapeptide Nootropic | not-approved | moderate | Approved as a medicinal product in the Russian Federation (essential drugs list, post-stroke + cognitive rehabilitation indications). Unapproved in UK, US, EU — research use only. |
| Peptide | SS-31 (Elamipretide) — Cardiolipin-Targeted Mitochondrial Peptide | not-approved | moderate | Phase III clinical-trial pipeline (Stealth BioTherapeutics) for primary mitochondrial myopathy and other indications. Not FDA/EMA/MHRA-approved as of May 2026. Research-grade material remains research-only. |
| Peptide | TB-500 — Thymosin β-4 (1-4) Synthetic Fragment | not-approved | moderate | Unapproved research compound in UK, US, EU. Laboratory and in vitro research use only. |
| Peptide | Thymalin — Thymic Peptide Complex Bioregulator | not-approved | moderate | Approved as a medicinal product in the Russian Federation. Unapproved in UK, US, EU — research use only. |
| Stack | BPC-157 + GHK-Cu — Research Evidence Review: Follicular Mechanisms & Evidence Limits | not-approved | moderate | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | BPC-157 + TB-500 + GHK-Cu — Research Evidence Review: Tissue-Repair & Remodelling Mechanisms | not-approved | moderate | Direct combination evidence is limited (mostly preclinical / small-trial). |
| Stack | BPC-157 + TB-500 — Research Evidence Review: Tissue-Repair Mechanisms & Translational Limits | not-approved | moderate | Direct combination evidence is limited (mostly preclinical / small-trial). |
| Stack | DSIP + Selank — Research Evidence Review: Sleep & Anxiolytic Mechanisms | not-approved | moderate | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | Epitalon + Humanin + MOTS-c — Research Evidence Review: Mitochondrial & Telomeric Mechanisms | not-approved | moderate | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | Epithalon + Thymalin — Research Evidence Review: Khavinson Bioregulator Mechanisms | not-approved | moderate | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | GHK-Cu + TB-500 — Research Evidence Review: Dermal Remodelling Mechanisms | not-approved | moderate | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | Ipamorelin + CJC-1295 + BPC-157 — Research Evidence Review: GH Axis + Tissue-Repair Mechanisms | not-approved | moderate | Direct combination evidence is limited (mostly preclinical / small-trial). |
| Stack | KPV + LL-37 — Research Evidence Review: Mucosal & Antimicrobial Mechanisms | not-approved | moderate | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | MOTS-c + AOD-9604 — Research Evidence Review: Mitochondrial & Lipolytic Mechanisms | not-approved | moderate | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | SS-31 + Humanin — Research Evidence Review: Mitochondrial Mechanisms | not-approved | moderate | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | SS-31 + MOTS-c — Research Evidence Review: Mitochondrial Cardiovascular Mechanisms | not-approved | moderate | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | Semax + Selank + Pinealon — Research Evidence Review: Neuropeptide Mechanisms & Translational Limits | not-approved | moderate | No direct combination studies; mechanism is inferred from monotherapy literature. |
| Stack | TB-500 + BPC-157 — Research Evidence Review: Tendon Repair Mechanisms & Study Models | not-approved | moderate | Direct combination evidence is limited (mostly preclinical / small-trial). |